MOLN
NASDAQMolecular Partners AG
Molecular Partners AG (MOLN) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for MOLN, including 4 press releases and news items and 1 SEC filing. The most recent was published Nov 6, 2026.
Financial highlights
Full financials- Revenue, FY2025
- CHF 0
- Revenue growth
- -100.0%
- Net income, FY2025
- -CHF 61.65M
- Free cash flow, FY2025
- -CHF 51.97M
- Cash
- CHF 82.65M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks16+100%
2026-05-172026-11-08
Mix790d
- Other5(71%)
- SEC Filings2(29%)
Activity · 52 weeks4330 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRMolecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagersFavorable safety profile, with new data indicating healthy tissues expressing either TAA remain intactAttractive therapeutic window underlines MP0632’s readiness for IND-enabling studies in solid tumors co-expressing MSLN and EpCAM ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), today annou
- PRMolecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will hold presentations on its lead Radio-DARPin candidate MP0712, co-developed with Orano Med, at two upcoming scientific conferences, including the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Theranostics Conference, taking place November 4–7 in Bethesda, MD, USA and the IASLC/ASCO 2026 North America Conference on Lung Cancer (NACLC), taking place December 4–6 in Scottsdale, AZ, USA. De
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted RadiotherapyDosing ongoing in fully recruited dose level 2 of MP0712 Phase 1/2a study; initial safety data to be presented at North America Conference on Lung Cancer in December 2026, efficacy data expected in 2027Emerging clinical data from lead Radio-DARPin candidate MP0712 enables strategic focus on radiopharmaceuticalsStreamlining of organization, in line with corporate focus, to advance Radio-DARPin programsCash position of CHF 57.5 million (USD ~69 million) as of September 30, 2026, expected to fund operations into late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX, NASDAQ:MOLN), a
- PRMolecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70Attractive biodistribution supports selection of MP0730 as Radio-DARPin therapy candidate CD70 is a clinically validated target expressed in kidney cancer and other indicationsFirst-in-human program expected to start in H2 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the selection of MP0730 as its lead Radio-DARPin candidate targeting the tumor-associated antigen CD70. MP0730 is the third program in the Company’s pipeline of targeted alpha rad
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a StudyDLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in 2027Cash position of CHF 67.9 million (USD ~84 million) as of June 30, 2026, expected to fund operations into late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecul
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with CholangiocarcinomaRandomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoingData update expected in 2027, with trial completion in 2028Trial-in-progress poster to be presented at ESMO 2026 in October ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announces the dosing of first patients in an investigator-initiated Phase 2 proof-of-concept (POC)
- PRMolecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin RadiotherapeuticsPhase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027Additional compassionate care work now initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectorsFIH imaging for MP0726, Radio-DARPin targeting MSLN, planned to start in H2 2026New target nomination in H2 2026, with two INDs planned in 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursua
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cyclesInitial data anticipated within the coming months, comprehensive efficacy data expected in 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners"), and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the developme
- SECSEC Form S-8 filed by Molecular Partners AGS-8 - MOLECULAR PARTNERS AG (0001745114) (Filer)
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. ASCO takes place May 29-June 2 in Chicago, and SNMMI May 30-Ju
- PRMolecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation SummitZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced that members of the management team will participate in the following upcoming investor conference. TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Fireside chat on Wednesday, May 27, 2026 beginning at 11:30am ET The event will be webcast and available on the Molecular Partners website, under the investors tab. About Molecular Partners AG Molecular Partners AG
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple clinical sites opening and initial clinical data expected in 2026New data on Radio-DARPins' amenability to range of therapeutic payloads enable isotope-agnostic strategy for expanding pipeline Strong financial position with cash including short-term time deposits of CHF 79 million (approx. USD 100 million), providing runway until late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin ther
- PRMolecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferencesZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics, today announced its attendance and presentations on its lead Radio-DARPin candidate MP0712 at upcoming scientific conferences. Details of the events: NIH National Cancer Institute 2026 Small Cell Lung Cancer Consortium Meeting May 6–7, Rockville, MD, USA Title: Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC) Session: New Therapy Targe
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodelingPositive Phase 1 data confirm MP0317's tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer typesPharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitorsRandomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or t
- PRMolecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the presentation of new p
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General MeetingZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced that Clare Fisher was elected by shareholders to its Board of Directors at the Annual General Meeting (AGM). The appointment, and all other motions proposed by the Board of Directors at the AGM, were approved by the shareholders of the Company by a wide majority. "Clare Fisher is an outstanding addition to our Board and we warmly welcome her.
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
MOLN FAQ
11 questionsWhat does Molecular Partners AG do?
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist...What is the latest news on MOLN?
In the last 30 days Quantisnow tracked 5 wire items for MOLN: 4 press releases and news items and 1 SEC filing. The most recent was published on November 6, 2026.What is MOLN revenue?
Molecular Partners AG (MOLN) reported CHF 0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is MOLN profitable?
No. Molecular Partners AG reported a net loss of CHF 61.65M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does MOLN have?
Molecular Partners AG reported CHF 82.65M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does MOLN stock trade?
Molecular Partners AG (MOLN) is listed on NASDAQ.What sector and industry is MOLN in?
Molecular Partners AG operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Molecular Partners AG go public?
Molecular Partners AG (MOLN) completed its IPO in 2021.What are analysts saying about MOLN?
Across the last 5 analyst actions on Molecular Partners AG, there was 1 upgrade and 3 downgrades. The most recent action was from H.C. Wainwright: Buy with a $13.00 price target on 2026-01-27. Recent price targets range from $8.00 to $13.00.What companies are similar to MOLN?
Notable peers in the same industry include AMGN (Amgen Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare MOLN side-by-side with any of them on Quantisnow.How can I track MOLN on Quantisnow?
Quantisnow aggregates Molecular Partners AG's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MOLN to receive live email and push alerts on every new disclosure.